DDInter1088 DDInter1676
Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Loperamide {u} (Compound) resembles {v} (Compound) Methadyl Acetate
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextropropoxyphene
Loperamide {u} (Compound) resembles {v} (Compound) Clofedanol
Loperamide {u} (Compound) binds {v} (Gene) CYP3A4
Loperamide {u} (Compound) upregulates {v} (Gene) SQLE
Loperamide {u} (Compound) is included by {v} (Pharmacologic Class) Opioid Agonists
Loperamide {u} (Compound) downregulates {v} (Gene) MRPL12
Loperamide {u} (Compound) causes {v} (Side Effect) Nausea
Loperamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cholestyramine
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Loperamide (Compound) resembles Methadyl Acetate (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene
Loperamide (Compound) resembles Clofedanol (Compound)
Loperamide (Compound) binds CYP3A4 (Gene)
Loperamide (Compound) upregulates SQLE (Gene)
Loperamide (Compound) is included by Opioid Agonists (Pharmacologic Class)
Loperamide (Compound) downregulates MRPL12 (Gene)
Loperamide (Compound) causes Nausea (Side Effect)
Loperamide may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor